AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Clinical trial NCT06511869 · COMPLETED

Trial details

NCT number: NCT06511869
Sponsor: Dizal Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma

Start date: 2022-03-17
Primary completion: 2025-03-31
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.